U.S. markets closed

Titan Pharmaceuticals, Inc. (TTNP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9296-0.0604 (-6.10%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.9900
Bid0.9140 x 1400
Ask1.0500 x 1200
Day's Range0.9134 - 1.0000
52 Week Range0.9100 - 4.6100
Avg. Volume366,911
Market Cap9.216M
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
EPS (TTM)-1.0670
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TTNP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Titan Pharmaceuticals, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • PR Newswire

    Titan Pharmaceuticals to Explore Strategic Alternatives

    Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan has engaged Maxim Group LLC as its exclusive financial advisor to assist in this process.

  • PR Newswire

    Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

    Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neuroscience 2021 Meeting, Ben Land, Ph.D., Research Assistant Professor at the University of Washington's Department of Pharmacology, reported additional positive data from an ongoing in vivo study of its human kappa-opioid receptor agonist ("TP-2021") ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model.

  • PR Newswire

    Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

    Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura®-based TP-2021 implant in an established animal model of chronic pruritus will be presented at the Society for Neuroscience 2021 Meeting, being held virtually, on November 8.